Alfred Scheidegger

Advisor

2024 - Current

Engineering Clinically Benchmarked ex vivo Breast Tumors in Human Breast Tissue Keliomics offers paradigm-shifting technology that revolutionizes cancer treatment by keeping human tissues alive outside the human body.

Member of the Advisory Board

2024

A Drug Candidate Marketplace for Licensing, Co-Development Partnerships and Investments. At the forefront of innovation, BioNeex stands as the biopharma industry’s premier R&D business development platform. Our dynamic digital meeting space empowers biotech firms, biopharma enterprises, and research academies to foster licensing, co-development alliances, and an array of collaborative ventures.

Chairman of the Board of Directors

2023

Wemedoo is a SaaS health-tech company focusing on clinical, medical, and real-world data and its interoperability. We empower hospitals, biopharmaceutical companies, clinical research organizations, and academia to effortlessly collect, analyze, and exchange all internal data to generate actionable insights across all workflows in real-time.

Founder, Member of the Board of Directors

1998

Founder, Managing Partner

1998 - 2023

Nextech Invest is a global active investment advisor in healthcare with a focus on oncology, run by an experienced multinational team of industry experts and supported by leading key opinion leaders. The skill-balanced team with a wealth of operational experience, a global network and a sound track record is responsible for the investments of the funds managed and advised by Nextech Invest Ltd. Their expertise, entrepreneurial values and commitment are the basis of returns for our investors. We deploy our expertise in oncology to invest equity in cancer companies with leadership teams active in the fields of therapy, medical technology, diagnostics and services, supported by a coherent and eminent group of six oncology experts. We enjoy working closely with our investors, scientific advisors, portfolio companies and other business partners.

Vice Chairman of the Board of Directors

2011 - 2024

DOTTIKON EXCLUSIVE SYNTHESIS (SIX: DESN) is a fine chemical company, specializing in hazardous, safety-critical chemical reactions focused on the exclusive synthesis of fine chemicals - providing custom manufacturing of APIs and advanced intermediates to major pharmaceutical and industrial companies around the world.

Senior Advisor

2021 - 2022

Member of the Foundation Board

2017 - 2021

Rising Tide Foundation Group (RTF Group) is an empowering global group of organizations established by an entrepreneur who sees an opportunity when others see impossibility. To advance and pioneer positive change in healthcare, and maximize opportunities to empower individuals to take charge of their lives and become the change they want to see.

Member of the Board Of Directors

2016 - 2019

Developing Novel Protein Degradation, Inhibitors for the Treatment of Cancer. Cleave Biosciences is focused on mining novel targets in cellular protein homeostasis pathways utilized by cancer cells for their growth and survival.

Observer of the Board of Directors

2012 - 2016

MolecularMD is a vertically integrated molecular diagnostics company focusing on oncology. Founded in 2005, it provides molecular testing to enable clinical decisions for the use of the right targeted cancer therapeutic based on genetic mutations determined from a patient sample. In addition, it allows for quantitatively monitoring the effect of the therapeutic to allow switching to a different therapeutic at the onset of resistance. The major focus has been on providing testing for clinical trials of novel targeted cancer therapies. In addition, the company is developing companion diagnostics and provides testing to medical doctors.

Member of the Board of Directors

2012 - 2015

TRACON Pharmaceuticals (Nasdaq: TCON) develops targeted therapies for people with cancer and related diseases. The current pipeline has two clinical-stage product candidates, each addressing a unique cellular process that is expected to complement currently available therapies. TRACON aims to develop effective and well-tolerated treatments for underserved populations with the ultimate goal of enhancing survival and quality of life while maximizing shareholder value.